Capsida Biotherapeutics Opens New Facility In Thousand Oaks

Thousand Oaks-based biotech company Capsida Biotherapeutics says it has opened up a new, 15,000 square-foot facility in Thousand Oaks for its gene therapy manufacturing efforts. The company is developing targeted adeno-associated virus (AAV) gene therapies for patients with debilitating and life-threatening genetic disorders. The company says that building its own manufacturing facility will help it eliminate dependence on ontract manufacturing. Capsida said the new 15,000 square-foot good manufacturing practice (GMP) manufacturing facility includes two ballroom production suites, a fill suite, and an in-house quality-control laboratory.